BNP Paribas Asset Management
LENZ

BNP Paribas Asset Management’s LENZ Therapeutics LENZ Stock Holding History

BNP Paribas Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-312
Closed -$5K – 2342
2025
Q4 		$5K Buy
312
+178
+133% +$5.19K ﹤0.01% 2263
2025
Q3 		$6K Sell
134
-38
-22% -$1.4K ﹤0.01% 1804
2025
Q2 		$5K Buy
+172
New +$4.68K ﹤0.01% 2058

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

BNP Paribas Asset Management's LENZ Position: Q1 2026 in Review

BNP Paribas Asset Management sold out of LENZ Therapeutics (LENZ) in Q1 2026, closing a stake of 312 shares — an estimated $5K sold.

BNP Paribas Asset Management first reported a position in LENZ in Q2 2025 and held it in 3 quarters. The position peaked at $6K in Q3 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

  • BNP Paribas Asset Management reported no remaining LENZ Therapeutics position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas Asset Management sold 312 LENZ Therapeutics shares in Q1 2026, an estimated $5K.
  • BNP Paribas Asset Management first reported a position in LENZ Therapeutics in Q2 2025 and held it in 3 quarters.
  • BNP Paribas Asset Management's LENZ Therapeutics position peaked at $6K in Q3 2025.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.